Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis
Open accessAbstract
Accumulation of cytotoxic bile acids (BAs) during cholestasis can result in liver failure. Glucuronidation, a phase II metabolism pathway responsible for BA detoxification, is regulated by peroxisome proliferator–activated receptor alpha (PPARα). This study investigates the efficacy of adjunct fenofibrate therapy to up‐regulate BA‐glucuronidation and reduce serum BA toxicity during cholestasis. Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13‐15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1.5 times the upper limit of normal, received additional fenofibrate (145‐160 mg/day) as standard of care. Serum BA and BA‐glucuronide concentrations were measured by liquid chromatography–mass spectrometry. Combination therapy with fenofibrate significantly decreased elevated serum ALP (−76%, P < 0.001), aspartate transaminase, alanine aminotransferase, bilirubin, total serum BAs (−54%), and increased serum BA‐glucuronides (+2.1‐fold, P < 0.01) versus ursodiol monotherapy. The major serum BA‐glucuronides that were favorably altered following adjunct fenofibrate include hyodeoxycholic acid–6G (+3.7‐fold, P < 0.01), hyocholic acid–6G (+2.6‐fold, P < 0.05), chenodeoxycholic acid (CDCA)–3G (−36%), and lithocholic acid (LCA)–3G (−42%) versus ursodiol monotherapy. Fenofibrate also up‐regulated the expression of uridine 5′‐diphospho‐glucuronosyltransferases and multidrug resistance–associated protein 3 messenger RNA in primary human hepatocytes. Pearson’s correlation coefficients identified strong associations between serum ALP and metabolic ratios of CDCA‐3G (r 2 = 0.62, P < 0.0001), deoxycholic acid (DCA)‐3G (r 2 = 0.48, P < 0.0001), and LCA‐3G (r 2 = 0.40, P < 0.001), in ursodiol monotherapy versus control. Receiver operating characteristic analysis identified serum BA‐glucuronides as measures of response to therapy. Conclusion: Fenofibrate favorably alters major serum BA‐glucuronides, which correlate with reduced serum ALP levels and improved outcomes. A PPARα‐mediated anti‐cholestatic mechanism is involved in detoxifying serum BAs in patients with PBC and PSC who have an incomplete response on ursodiol monotherapy and receive adjunct fenofibrate. Serum BA‐glucuronides may serve as a noninvasive measure of treatment response in PBC and PSC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PPAR-α activation enhances bile acid metabolism and secretion.
“PPAR-α activation enhances bile acid metabolism and secretion [33,34].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
2 retracted
Metabolomics reveals that PPARα activation protects against lithocholic acid-induced liver injury
Zhao, Q., Yang, R., Liu, F., Wang, J., Hu, D., Yang, X., & Li, F. (2017) · RSC Advances · doi:10.1039/c7ra08823j · Cited by 25 · see citing works
RetractedQi, Z., Yang, R., Liu, F., Wang, J., Hu, D., Yang, X., & Li, F. (2023) · RSC Advances · doi:10.1039/d3ra90008h · Cited by 6 · see citing works
Retractedlimma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796 · see citing works
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · see citing works
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 635 · see citing works
Intestinal transport and metabolism of bile acids
Dawson, P. A., & Karpen, S. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r054114 · Cited by 598 · see citing works
UDP-glucuronosyltransferases and clinical drug-drug interactions
Kiang, T. K. L., Ensom, M. H. H., & CHANG, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.013 · Cited by 554 · see citing works
plotROC: A Tool for Plotting ROC Curves
Sachs, M. C. (2017) · Journal of Statistical Software · doi:10.18637/jss.v079.c02 · Cited by 391 · see citing works
Induction of bilirubin clearance by the constitutive androstane receptor (CAR)
Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., & Moore, D. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630614100 · Cited by 390 · see citing works
Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
Rakhshandehroo, M., Hooiveld, G. J. E. J., Müller, M. M., & Kersten, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006796 · Cited by 307 · see citing works
Inherited disorders of bilirubin metabolism
Bosma, P. J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279 · see citing works
Ritter, J. K., Crawford, J. M., & Owens, I. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35280-8 · Cited by 261 · see citing works
Cai, S., Ouyang, X., Chen, Y., Soroka, C. J., Wang, J., Mennone, A., Wang, Y., Mehal, W. Z., Jain, D., & Boyer, J. L. (2017) · JCI Insight · doi:10.1172/jci.insight.90780 · Cited by 258 · see citing works
Self-citationHonda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210 · see citing works
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · see citing works
Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans
Luo, L., Aubrecht, J., Li, D., Warner, R. L., Johnson, K. J., Kenny, J., & Colangelo, J. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193824 · Cited by 165 · see citing works
Trottier, J., Bialek, A. P., Caron, P., Straka, R. J., Heathcote, J., Milkiewicz, P., & Barbier, O. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.10.025 · Cited by 157 · see citing works
Self-citationSong, P., Zhang, Y., & Klaassen, C. D. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr177 · Cited by 155 · see citing works
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Klein, K., Thomas, M., Winter, S., Nussler, A. K., Niemi, M., Schwab, M. G., & Zanger, U. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.336 · Cited by 153 · see citing works
Protective Role of Hydroxysteroid Sulfotransferase in Lithocholic Acid-induced Liver Toxicity
Kitada, H., Miyata, M., Nakamura, T., Tozawa, A., Honma, W., Shimada, M., Nagata, K., Sinal, C. J., Guo, G. L., Gonzalez, F. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210634200 · Cited by 151 · see citing works
Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7
Gall, W. E., Zawada, G., Mojarrabi, B., Tephly, T. R., Green, M. D., Coffman, B. L., Mackenzie, P. I., & Radominska-p, A. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00088-6 · Cited by 145 · see citing works
Barbier, O., Durán-Sandoval, D., Pineda‐Torra, I., Kosykh, V., Fruchart, J., & Staels, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305361200 · Cited by 142 · see citing works
Self-citationSenekeo‐Effenberger, K., Chen, S., Brace‐Sinnokrak, E., Bonzo, J. A., Yueh, M., Argikar, U. A., Kaeding, J., Trottier, J., Remmel, R. P., Ritter, J. K., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013243 · Cited by 119 · see citing works
Self-citationWoolbright, B. L., Li, F., Xie, Y., Farhood, A. I., Fickert, P., Trauner, M. A., & Jaeschke, H. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.04.001 · Cited by 94 · see citing works
Woolbright, B. L., McGill, M. R., Staggs, V. S., Winefield, R. D., Gholami, P., Olyaee, M. S., Sharpe, M. R., Curry, S. C., Lee, W. M., Jaeschke, H., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu195 · Cited by 88 · see citing works
Ghonem, N. S., Ananthanarayanan, M., Soroka, C. J., & Boyer, J. L. (2013) · Hepatology · doi:10.1002/hep.26894 · Cited by 86 · see citing works
Self-citationLipid-activated transcription factors control bile acid glucuronidation
Barbier, O., Trottier, J., Kaeding, J., Caron, P., & Verreault, M. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0001-5 · Cited by 78 · see citing works
Self-citationLemoinne, S., Pares, A., Reig, A., Ben Belkacem, K., Kemgang Fankem, A. D., Gaouar, F., Poupon, R., Housset, C., Corpechot, C., & Chazouillères, O. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.06.009 · Cited by 74 · see citing works
Verreault, M., Senekeo‐Effenberger, K., Trottier, J., Bonzo, J. A., Bélanger, J., Kaeding, J., Staels, B., Caron, P., Tukey, R. H., & Barbier, O. (2006) · Hepatology · doi:10.1002/hep.21259 · Cited by 72 · see citing works
Self-citationSafety of fibrates in cholestatic liver diseases
Carrion, A. F., Lindor, K. D., & Levy, C. (2021) · Liver International · doi:10.1111/liv.14871 · Cited by 72 · see citing works
Circulating bile acids predict outcome in critically ill patients
Horvatits, T., Drolz, A., Rutter, K., Roedl, K., Langouche, L., den Berghe, G. V., Fauler, G., Meyer, B., Hülsmann, M., Heinz, G., et al. (2017) · Annals of Intensive Care · doi:10.1186/s13613-017-0272-7 · Cited by 71 · see citing works
Horvatits, T., Drolz, A., Roedl, K., Rutter, K., Ferlitsch, A., Fauler, G., Trauner, M. A., & Fuhrmann, V. (2016) · Liver International · doi:10.1111/liv.13201 · Cited by 65 · see citing works
Coordinate Regulation of Hepatic Bile Acid Oxidation and Conjugation by Nuclear Receptors
Trottier, J., Milkiewicz, P., Kaeding, J., Verreault, M., & Barbier, O. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060020t · Cited by 58 · see citing works
Self-citationGhonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57 · see citing works
Self-citationDai, M., Yang, J., Xie, M., Lin, J., Luo, M., Hua, H., Xu, G.-M., Lin, H., Song, D., Cheng, Y., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13928 · Cited by 54 · see citing works
Manna, L., Ovadia, C., Lövgren‐Sandblom, A., Chambers, J. J. G., Begum, S., Seed, P. T., Walker, I. A. L., Chappell, L. C., Marschall, H., & Williamson, C. (2019) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15926 · Cited by 52 · see citing works
Perreault, M., Bialek, A. P., Trottier, J., Verreault, M., Caron, P., Milkiewicz, P., & Barbier, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080994 · Cited by 50 · see citing works
Self-citationBock, K. W. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.009 · Cited by 50 · see citing works
Trottier, J., Perreault, M., Rudkowska, I., Levy, C., Dallaire-Théroux, A., Verreault, M., Caron, P., Staels, B., Vohl, M., Straka, R. J., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.122 · Cited by 48 · see citing works
Self-citationMetabolic Profiling of Bile Acids in the Urine of Patients with Alcohol-Associated Liver Disease
He, L., Vatsalya, V., Ma, X., Zhang, J., Yin, X., Kim, S., Feng, W., McClain, C. J., & Zhang, X. (2021) · Hepatology Communications · doi:10.1002/hep4.1671 · Cited by 22 · see citing works
Lithocholate-3-O-glucuronide-induced cholestasis
Takikawa, H., Minagawa, K., Sano, N., & Yamanaka, M. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01308618 · Cited by 19 · see citing works
Why bile acid glucuronidation is a minor pathway for conjugation of endogenous bile acids in man†
Hofmann, A. F. (2007) · Hepatology · doi:10.1002/hep.21576 · Cited by 18 · see citing works
Mostarda, S., Passeri, D., Carotti, A., Cerra, B., Colliva, C., Benicchi, T., Macchiarulo, A., Pellicciari, R., & Gioiello, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.034 · Cited by 18 · see citing works
Perreault, M., Wunsch, E., Bialek, A. P., Trottier, J., Verreault, M., Caron, P., Poirier, G. G., Milkiewicz, P., & Barbier, O. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8096314 · Cited by 17 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Liu, Y., Guo, G., Zheng, L., Sun, R., Wang, X., Deng, J., Jia, G., Yang, C., Cui, L., Guo, C., et al. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002238 · Cited by 55 · see citing works
Recent Advances in the Management of Primary Sclerosing Cholangitis
Assis, D. N., & Bowlus, C. L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.004 · Cited by 55 · see citing works
Self-citationGallucci, G. M., Alsuwayt, B., Auclair, A. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2022) · Inflammation · doi:10.1007/s10753-022-01713-1 · Cited by 46 · see citing works
Self-citationPPARα: A potential therapeutic target of cholestasis
Ye, X., Zhang, T., & Han, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.916866 · Cited by 43 · see citing works
Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024) · Cells · doi:10.3390/cells13151296 · Cited by 40 · see citing works
Self-citationPPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 30 · see citing works
Self-citationLiu, F., Yao, Y., Wang, Q., Zhang, F., Wang, M., Zhu, C., & Lin, C. (2022) · Phytotherapy Research · doi:10.1002/ptr.7588 · Cited by 29 · see citing works
The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism
Sun, Y., Zhang, L., & Jiang, Z. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13971 · Cited by 27 · see citing works
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
Bhushan, S. R., Sohal, A., & Kowdley, K. V. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003174 · Cited by 29 · see citing works
Han, X., Wang, J., Gu, H., Guo, H., Cai, Y., Liao, X., & Jiang, M. (2022) · Metabolomics · doi:10.1007/s11306-022-01890-y · Cited by 21 · see citing works
Wang, X., Klaassen, C. D., Chen, X., & Zhang, Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100073 · Cited by 17 · see citing works
Suppression of Hepatic PPARα in Primary Biliary Cholangitis Is Modulated by miR-155
Adamowicz, M., Kempińska‐Podhorodecka, A., Abramczyk, J., Bañales, J. M., Milkiewicz, P., & Milkiewicz, M. (2022) · Cells · doi:10.3390/cells11182880 · Cited by 16 · see citing works
Peroxisome proliferator–activated receptor delta and liver diseases
Yamazaki, T., Cable, E. E., & Schnabl, B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000646 · Cited by 12 · see citing works
Management of primary sclerosing cholangitis: Current state-of-the-art
Cançado, G. G. L., & Hirschfield, G. M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000590 · Cited by 11 · see citing works
PPARα agonist ameliorates cholestatic liver injury by regulating hepatic macrophage homeostasis
Shi, Q., Chen, X., Zeng, Y., Chu, Q., Jiang, S., Zhang, Y., Yuan, X., Zhu, D., & Li, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138510 · Cited by 9 · see citing works
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6 · see citing works
Cançado, G. G. L., Chen, B., Cameron, M., Houri, I., Leung, K. K., Gulamhusein, A. F., Hansen, B. E., & Hirschfield, G. M. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000798 · Cited by 4 · see citing works
Jalan‐Sakrikar, N., Anwar, A. A., Ali, A., Nasser‐Ghodsi, N., Felzen, A., Huebert, R. C., LaRusso, N. F., & O’Hara, S. P. (2026) · Physiological Reviews · doi:10.1152/physrev.00022.2025 · Cited by 2 · see citing works
Li, W., Gong, X., Niu, X., Zhou, Y., Ren, L., Man, Z., Tu, P., Xiong, X., Liu, W., & Song, Y. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05430-6 · Cited by 2 · see citing works
Li, Y., Tian, C., Song, X., Du, M., Zhang, G., & Liu, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s395114 · Cited by 2 · see citing works
Bile acid metabolism and signaling in human and animal health: A One Health perspective
Li, L., Liu, S., Cao, Z., Cao, Y., Wu, S., Deng, L., Yao, J., & Zhang, J. (2026) · iMetaOmics. · doi:10.1002/imo2.70123 · Cited by 1 · see citing works
Scheinberg, A. R., & Levy, C. (2022) · Current treatment options in gastroenterology · doi:10.1007/s11938-022-00384-z · Cited by 355 · see citing works
PPAR-Agonisten - etablierte Substanzen und neue Entwicklungen
Herta, T., & Tacke, F. (2025) · Gastro-News · doi:10.1007/s15036-025-3896-8
The emerging role of PPARs in primary biliary cholangitis
Palomer, X., Rodríguez‐Calvo, R., Mateo, S. G., Wahli, W., & Vázquez‐Carrera, M. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.008
Author’s reply: “Fibrate therapy in primary sclerosing cholangitis"
Catanzaro, E., & Cazzagon, N. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.07.004
Hayes, C. M., Cross, D. R., Achour, B., & Ghonem, N. S. (2026) · Cells · doi:10.3390/cells15161442
Self-citation
- Authors
- Gallucci, G. M., Trottier, J., Hemme, C., Assis, D. N., Boyer, J. L., Barbier, O., & Ghonem, N. S.
- Affiliations
- University of Rhode Island (US)
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Yale University (US)
- Université Laval (CA)
- Corresponding author
- Ghonem, Nisanne S.
- ORCID
- Venue
- Hepatology Communications
- Published
- 2021-08-27
- Volume
- 5
- Issue
- 12
- Pages
- 2035-2051
- ISSN
- 2471-254X (ISSN-L)
- PMC
- PMC8631103
- OpenAlex
- W3197532225
- Cited by
- 26
- References
- 44
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Hepatology Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Journal of Media Literacy Education (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (UL1TR001863)
- National Institute of General Medical Sciences (P20GM103430)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-34989, P30DK034989)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- fenofibrate, cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis, ursodeoxycholic acid, PPARα, bile acid detoxification, UGT enzymes, MRP3, serum alkaline phosphatase, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, hyodeoxycholic acid
- MeSH terms
- Adult, Bile Acids and Salts, Cholestasis, Drug Therapy, Combination, Female, Humans, Liver, Liver Cirrhosis, Biliary, Liver Function Tests, Male, Middle Aged, Fenofibrate, Retrospective Studies, Ursodeoxycholic Acid, Cholangitis, Sclerosing, Up-Regulation, Treatment Outcome, Glucuronides, Hepatocytes, PPAR alpha, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
